The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Open accessAbstract
BACKGROUND: Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS: We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse during the 12-month period before randomization to receive continued interferon beta-1a in combination with 300 mg of natalizumab (589 patients) or placebo (582 patients) intravenously every 4 weeks for up to 116 weeks. The primary end points were the rate of clinical relapse at 1 year and the cumulative probability of disability progression sustained for 12 weeks, as measured by the Expanded Disability Status Scale, at 2 years. RESULTS: Combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02). Kaplan-Meier estimates of the cumulative probability of progression at two years were 23 percent with combination therapy and 29 percent with interferon beta-1a alone. Combination therapy was associated with a lower annualized rate of relapse over a two-year period than was interferon beta-1a alone (0.34 vs. 0.75, P<0.001) and with fewer new or enlarging lesions on T(2)-weighted magnetic resonance imaging (0.9 vs. 5.4, P<0.001). Adverse events associated with combination therapy were anxiety, pharyngitis, sinus congestion, and peripheral edema. Two cases of progressive multifocal leukoencephalopathy, one of which was fatal, were diagnosed in natalizumab-treated patients. CONCLUSIONS: Natalizumab added to interferon beta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing multiple sclerosis. Additional research is needed to elucidate the benefits and risks of this combination treatment. (ClinicalTrials.gov number, NCT00030966.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Self-citationA Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationIntramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Self-citationThe IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Self-citationWEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G., & Janeway, C. A. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.57 · Cited by 835
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Self-citationCarman, C. V., & Springer, T. A. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200404129 · Cited by 658
The pathophysiologic role of alpha 4 integrins in vivo.
Lobb, R. R., & Hemler, M. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117519 · Cited by 378
Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
Rudick, R., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Fischer, J., Lublin, F., Miller, A., Petkau, J., Rao, S., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410420318 · Cited by 371
Self-citationProgressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
Berger, J. R., & Koralnik, I. J. (2005) · New England Journal of Medicine · doi:10.1056/nejme058122 · Cited by 271
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
Clanet, M., Radue, E. W., Kappos, L., Hartung, H. P., Hohlfeld, R., Sandberg-Wollheim, M., Kooijmans-Coutinho, M. F., Tsao, E. C., Sandrock, A. W., & the European IFNβ-1a (Avonex) Dose-Comparison Study Investigators* (2002) · Neurology · doi:10.1212/01.wnl.0000032256.35561.d6 · Cited by 220
Self-citationIn vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
Rudick, R. A., Ransohoff, R. M., Lee, J. C., Peppler, R., Yu, M., Mathisen, P. M., & Tuohy, V. K. (1998) · Neurology · doi:10.1212/wnl.50.5.1294 · Cited by 218
Self-citationDefining interferon β response status in multiple sclerosis patients
Rudick, R. A., Lee, J., Simon, J., Ransohoff, R. M., & Fisher, E. (2004) · Annals of Neurology · doi:10.1002/ana.20224 · Cited by 217
Self-citationCalabresi, P. A., Tranquill, L. R., Dambrosia, J. M., Stone, L. A., Maloni, H. W., Bash, C. N., Frank, J. A., & McFarland, H. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410517 · Cited by 157
Self-citationInterferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses
Beck, R. W., Chandler, D. L., Cole, S. R., Simon, J. H., Jacobs, L. D., Kinkel, R. P., Selhorst, J. B., ROSE, J. W., Cooper, J. A., Rice, G. P., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10148 · Cited by 128
Self-citationCalabresi, P. A., Pelfrey, C. M., Tranquill, L. R., Maloni, H. W., & McFarland, H. F. (1997) · Neurology · doi:10.1212/wnl.49.4.1111 · Cited by 123
Self-citationRep, M. H. G., Hintzen, R. Q., Polman, C. H., & van Lier, R. A. W. (1996) · Journal of Neuroimmunology · doi:10.1016/0165-5728(96)00060-4 · Cited by 119
Interferon beta induces T-helper 2 immune deviation in MS
Kozovska, M., Hong, J., Zang, Y. C. Q., Li, S., Rivera, V. M., Killian, J. M., & Zhang, J. Z. (1999) · Neurology · doi:10.1212/wnl.53.8.1692 · Cited by 111
Lehman, A. J., Esdaile, J. M., Klinkhoff, A. V., Grant, E., Fitzgerald, A. A., Canvin, J., & The METGO Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21018 · Cited by 103
Gerards, A., Landewé, R., Prins, A. P. A., Bruijn, G., Thé, H. S. G., Laan, R., & Dijkmans, B. A. C. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.4.291 · Cited by 101
Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-β
Zang, Y. C. Q., Halder, J., Samanta, A. K., et al. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00397-0 · Cited by 92
Traboulsee, A. L., Dehmeshki, J., Peters, K. R., Griffin, C., Brex, P., Silver, N., Ciccarelli, O., Chard, D., Barker, G. J., Thompson, A. J., et al. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms958oa · Cited by 90
Decreased integrin gene expression in patients with MS responding to interferon-β treatment
Muraro, P. A., Liberati, L., Bonanni, L., Pantalone, A., Caporale, C. M., Iarlori, C., Luca, G. D., Farina, D., Lugaresi, A., & Gambi, D. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.01.002 · Cited by 46
Vollmer, T. R., Phillips, J. T., Goodman, A. D., Agius, M. A., Libonati, M., Giacchino, J. L., & Grundy, J. S. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1084oa · Cited by 43
Correlations of brain MRI parameters to disability in multiple sclerosis
Schreiber, K. I., Sørensen, P. S., Koch‐Henriksen, N., Wagner, A., Blinkenberg, M., Svarer, C., & Petersen, H. C. (2001) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2001.00041.x · Cited by 41
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citation
Metadata
- Authors
- Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., & Sandrock, A. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-02
- Volume
- 354
- Issue
- 9
- Pages
- 911-923
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2019582599
- Cited by
- 1,344
- References
- 42
- FWCI
- 59.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.